Another name that insiders find very attractive here is biotechnology and drugs player Amicus Therapeutics (FOLD), which is focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration. Insiders are sniffing out some value here, since the stock has dropped over 20% in the last six months.
Amicus Therapeutics has a market cap of $230 million and an enterprise value of $124 million. This stock trades at a reasonable valuation, with a price-to-sales of 9.92 and a price-to-book of 2.85. Its estimated growth rate for this year is 15.6%, and for next year it's pegged at -5.6%. This is a cash-rich company, since the total cash position on its balance sheet is $108.20 million and its total debt is $1.73 million.>>4 Biotech Stocks Under $10 With Relative Strength A beneficial owner just bought 2,949,581 shares, or around $18.58 million worth of stock, at $6.30 per share. From a technical perspective, FOLD is currently trading below its 50-day moving average and just above its 200-day moving average, which is neutral trendwise. This stock has sold off hard over the last few trading sessions, with shares plunging from $6.89 to a recent low of $4.87 a share. That selloff has been accompanied with heavy selling volume, which is bearish technical action. That said, shares of FOLD have so far been defended right near its 200-day moving average of $4.77 a share. If you're in the bull camp on FOLD, I would look for long-biased trades if this stock can manage to hold a trend above its 200-day at $4.77 a share with strong upside volume flows. I would consider any upside volume day that registers near or above its three-month average action of 222,562 shares as bullish. If FOLD can manage to hold a trend above its 200-day, then I would look to add to any positions once it sustains a move or close back above its 50-day at $5.29 a share with heavy volume. If we get that action, then target a pop towards $6 or possibly a bit higher. On the flipside, I would avoid FOLD or look for short-biased trades if it fails to get back above its 50-day, and then takes out its 200-day at $4.77 a share with heavy volume. If we get that action, then FOLD will likely re-test its June low of $4.25 a share, or possibly even take that level out. Amicus shows up on a list of 22 Biopharma Stocks With Breakout Potential in 2012.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV